Biomedical Engineering Reference
In-Depth Information
Burton TM (2011) Many 'orphan drugs' get expedited review by FDA. Wall Street Journal
(October 12)
Coan TB, Ellis R (2001) Report for USA specialty pharmaceuticals: generic biologics: the next
frontier. Consumer project on technology. http://www.cptech.org/ip/health/biotech/gen-
bio062001.pdf . Accessed 17 Dec 2007
Conley JG, Orozco DM (2005) Intellectual property—the ground rules, Case No. KELI40 (01-01-
05, revised 30-08-05), Kellogg School of Management, Northwestern University, p. 1-40
Conley JG, Orozco DM (2007) Technical note: innovation and invention—a patent guide for
inventors and managers, Case No. KEL104 (08-01-07). Kellogg School of Management,
Northwestern University, p. 1-37
Conley JG, Szobocsan J (2001) Snow White shows the way. Manag Intellect Prop 06(01):1-5
Conley JG, Wong E, Wolcott RC (2006a) AstraZeneca, Prilosec and Nexium: strategic challenges
in the launch of a second-generation drug, Case Study 5-404-752 (revised Apr 2005), Kellogg
School of Management, Northwestern University
Conley JG, Wong E, Wolcott RC (2006b) Case supplement: AstraZeneca, Prilosec and Nexium,
Case Study 5-404-753. Kellogg School of Management, Northwestern University
Conley JG, Berry JD, DeWitt L, Dziersk M (2008) Inventing brands: opportunities at the nexus of
semiotics and intellectual property. Des Manage Rev 19(2):58-67
Department of Health and Human Services-Offi ce of Inspector General (2001) The orphan drug
act—implementation
and
impact.
http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf .
Accessed 8 Aug 2011
Eliashberg J, Jeuland AP (1986) The impact of competitive entry in a developing market upon
dynamic pricing strategies. Mark Sci 5(1):20-36
FDA (1999) Guidance for industry-qualifying for pediatric exclusivity under section 505A
of the Federal Food, Drug, and Cosmetic Act. http://www.fda.gov/downloads/Drugs/
DevelopmentApprovalProcess/DevelopmentResources/UCM049924.pdf . Accessed 8 Aug 2011
FDA (2003) Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman
Amendments). http://www.fda.gov/NewsEvents/Testimony/ucm115033.htm . Accessed 8 Aug 2011
FDA (2009) Frequently asked questions on pediatric exclusivity (505A), the pediatric
“rule,” and their interaction. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
DevelopmentResources/ucm077915.htm#Exclusivity . Accessed 8 Aug 2011
FTC (2002) Generic drug entry prior to patent expiration: an FTC study. http://www.ftc.gov/
os/2002/07/genericdrugstudy.pdf . Accessed 8 Aug 2011
FTC (2009) FTC issues interim report on “authorized generic” drugs. http://www.ftc.gov/
opa/2009/06/generics.shtm . Accessed 8 Aug 2011
Fugh-Berman A, Melnick D (2008) Off-label promotion, on-target sales. PLOS Med
5(10):1432-1435
Glover GJ (2007) The infl uence of market exclusivity on drug availability and medical innova-
tions. AAPS J. 9(3):312-316. http://www.aapsj.org/view.asp?art=aapsj0903034 . Accessed 8
Aug 2011
Gold R (2001) Aventis is Sued over alleged payments. Wall Street Journal (May 15)
Grabowski H, Vernon J, DiMasi JA (2002) Returns on research and development for 1990s new
drug introductions. Pharmacoeconomics 20 (Supplement 3): 11-29
Granstrand O (1999) The economics and management of intellectual property: towards intellectual
capitalism. Edward Elgar, Cheltenham, pp 247-251
Haffner ME, Janet W, Marie M (2002) Two decades of orphan product development. Nat Rev Drug
Discov 1:821-825
Harris G (2001) Bristol-Myers faces consumer lawsuits involving BuSpar. Wall Street Journal
(April 10)
Harris G (2002) Prilosec's maker switches users to nexium, thwarting generics. Wall Street Journal
(June 6)
Harris G, Rundle R (2000) Watson, Mylan suits target FDA over drug patent of Bristol-Myers.
Wall Street Journal (December 1)
Search WWH ::




Custom Search